PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
No Data
No Data available this quarter, please select a different quarter.
3.07
Dangerously high net debt exceeding 1.5x Biotechnology median of 1.74. Michael Burry would check for debt covenant compliance and refinancing risks.
No Data
No Data available this quarter, please select a different quarter.
4.95
Current ratio 1.25-1.5x Biotechnology median of 4.48. Philip Fisher would check if strong liquidity supports growth investments.
No Data
No Data available this quarter, please select a different quarter.